-+ 0.00%
-+ 0.00%
-+ 0.00%

HUTCHMED ANNOUNCES CHINA NMPA APPROVAL OF SYVIK® (SOVLEPLENIB) FOR THE TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA AND WARM ANTIBODY AUTOIMMUNE HEMOLYTIC ANEMIA

Reuters·11/19/2026 10:00:00

Please log in to view news